Track record · closed signal

Novo Nordisk A/S (NVO) — closed signal from January 19, 2026

Partial Published before the outcome was known, scored automatically when the window closed on April 19, 2026.

Predicted vs. what happened

NVO price · publication thesis → realized outcomesplit-adjusted
$62.79 Published $70.32 Target $40.52 Window close $64.16 Peak
$58.00 – $63.00Entry zone — fair-value band
$62.79Published — price the day we called it
$70.32Target — the price the thesis aimed for
$64.16Peak — highest point inside the window, not a realized return
$40.52Window close — end-of-window price, context only

What happened

Partial

Reached 18% of the predicted growth at its peak, without hitting the target.

Peak price
$64.16
peak on January 23, 2026 — not a realized return
Peak gain
+2.2%
peak, from the publication price
Window close
$40.52
end-of-window price, context only
Days to target
—
Window
January 19, 2026 – April 19, 2026

The thesis — published January 19, 2026

Predicted growth
+12%
over the measurement window
Target price
$70.32
the price the thesis aimed for
Entry zone
$58.00 – $63.00
the fair-value band we waited for
Price at publication
$62.79
published January 19, 2026
Confidence
63%
how strongly the data lined up
Timeframe
Short-term (0–3 months)

Novo Nordisk is a leader in diabetes and obesity medicines. Lots of investors are watching it, which can push the price up but also creates a crowded trade that can reverse fast if competitors announce news. The stock is currently high; it's safer to wait for a price dip before buying more and to watch headlines closely.

Primary drivers

  • Strong position in diabetes and obesity drugs keeps steady demand
  • High investor attention can keep momentum but also creates crowding
  • News about rival drugs can quickly reverse the stock's gains
  • Buying on pullbacks lowers risk compared with buying when extended

How it played out

NVO: the target was not reached

Lyra published NVO at 62.79 on 2026-01-19 with a short-term view. The thesis expected 12% growth and pointed to Novo Nordisk's diabetes and obesity medicines, high investor attention, risk from rival drug news, and the idea that pullbacks were safer than buying when extended.

Inside the window, NVO reached 64.16 on 2026-01-23, a peak gain of 2.2%. It stayed below the 70.32 target. By 2026-04-19, it ended at 40.52. The thesis missed on the target and the closing direction.

What happened during the window

On 2026-02-03, MarketWatch reported that Novo Nordisk released fourth-quarter results early and said it expected 2026 adjusted sales to fall by 5% to 13% from 2025 levels. The article also reported fourth-quarter sales of DKK74.1 billion and net profit of DKK26.9 billion.

Prices are shown split- and dividend-adjusted, matching what public charts show today.

Share this receipt

A scored call, published before the outcome was known. Paste the link anywhere — it unfurls as the card above.

Lyra

Read the next call before it closes.

This is one signal, scored after the fact. Today’s picks come with the same plain-language thesis — published before anyone knows the outcome.

See today’s picks All NVO signals